Cysticercosis medical therapy

Jump to navigation Jump to search

Cysticercosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cysticercosis from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Case Studies

Case #1

Cysticercosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cysticercosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cysticercosis medical therapy

CDC on Cysticercosis medical therapy

Cysticercosis medical therapy in the news

Blogs on Cysticercosis medical therapy

Directions to Hospitals Treating Cysticercosis

Risk calculators and risk factors for Cysticercosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]

Overview

Cysticercosis is generally treated with combination of both anti parasitic drugs and anti inflammatory drugs. Symptomatic treatment is the mainstay therapy for neurocysticercosis. Surgical removal sometimes necessary to treat ophthalmic cysticercosis and subcutaneous cysticercosis.

Medical Therapy

Neurocysticercosis

  • Neurocysticercosis most often presents as headaches and acute onset seizures, thus the immediate mainstay of therapy is anticonvulsant medications. *Once the seizures have been brought under control, antihelminthic treatments may be undertaken.
  • The decision to treat with antihelminthic therapy is complex and based on the stage and number of cysts present, their location, and the patient's specific clinical presentation.[1]
  • Antihelminthic therapy should be given in combination with corticosteroids and anticonvulsants to reduce inflammation surrounding the cysts and lower the risk of seizures.
  • Albendazole is generally preferable over praziquantel due to its lower cost and fewer drug interactions.[2]
  • Asymptomatic cysts, such as those discovered incidentally on neuroimaging done for another reason, may never lead to symptomatic disease and in many cases do not require therapy.
  • Calcified cysts have already died and involuted. Further antihelminthic therapy will be of no benefit.

Ocular cysticercosis

  • In ophthalmic disease, surgical removal is necessary for cysts within the eye itself.
  • Cysts outside the globe can be treated with antihelminthic drugs alone.

Subcutaneous cysticercosis

  • In general, the subcutaneous disease does not need specific therapy. Painful or bothersome cysts can be surgically excised.
  • Treatment recommendations for subcutaneous cysticercosis includes surgery, praziquantel and albendazole.

Antimicrobial Regimen

Neurocysticercosis

  • Neurocysticercosis treatment
  • 1. Parenchymal neurocysticercosis
  • 1.1 Single lesions[3]
  • Preferred regimen: Albendazole 15 mg/kg/day PO bid for 3-8 days AND Prednisone 1 mg/kg/day PO qid for 8-10 days followed by a taper
  • 1.2 Multiple cysts
  • 1.3 Cysticercal encephalitis [3]
  • 1.4 Calcified cysts
  • 2. Extraparenchymal NCC
  • 2.1 Subarachnoid cysts
  • 2.2 Giant cysts
  • 2.3 Intraventricular cysts
  • 2.4 Ocular cysticercosis
  • 2.5 Spinal cysticercosis

Contraindicated medications

Ocular cysticercosis is considered an absolute contraindication to the use of the following medications:

References

  1. White, Jr., A. Clinton (2009). "New developments in the management of neurocysticercosis". The Journal of Infectious Diseases. 199 (9): 1261. doi:10.1086/597758. PMID 19358667.
  2. Dimitrios K. Matthaiou, Georgios Panos, Eleni S. Adamidi,Matthew E. Falagas “Albendazole versus Praziquantel in the Treatment of Neurocysticercosis: A Meta-analysis of Comparative Trials” PLoS Negl Trop Dis. 2008 March; 2(3): e194
  3. 3.0 3.1 García HH, Evans CA, Nash TE, Takayanagui OM, White AC, Botero D; et al. (2002). "Current consensus guidelines for treatment of neurocysticercosis". Clin Microbiol Rev. 15 (4): 747–56. PMC 126865. PMID 12364377.


Template:WikiDoc Sources